2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Keratosis, Actinic
1
Fallopian Tube Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Lobular
1
Interventions
Letrozole
6
Radiotherapy
4
Carboplatin
4
atamestane
3
Trastuzumab
3
Toremifene
3
Magnetic Resonance Spectroscopy
3
Fulvestrant
3
Docetaxel
3
Cyclophosphamide
3
Chemotherapy, Adjuvant
3
Tamoxifen
2
Paclitaxel
2
Gene Expression Profiling
2
Estrogen Receptor Modulators
2
Capecitabine
2
Aromatase Inhibitors
2
Amplified Fragment Length Polymorphism Analysis
2
repotrectinib
1
proto-oncogene protein c-fes-fps
1
palbociclib
1
neratinib
1
gallium 68 PSMA-11
1
fluciclovine F-18
1
entrectinib
1
Zolpidem
1
Vorinostat
1
Vinorelbine
1
Venlafaxine Hydrochloride
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Lobular
×
Drugs, Generic
×
Clear all
NCT03620643
2025-10-30
ROLo
Royal Marsden NHS Foundation Trust
Phase 2
Completed
33 enrolled
13 charts